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ess: mkichael.d.spenceSummary The economic consequences of chronic obstructive pulmonary disease
(COPD) are considerable, although the factors that best predict costs are largely
unknown. This study used a population-based cohort to identify the clinical factors
during an index year that were most predictive of increased direct medical costs in
the subsequent year, and to develop a predictive model that described the cost
variations in COPD.
The medical records of 2116 patients enrolled in one regional health system who
had COPD and healthcare resource utilisation data for 1998 and 1999, were
abstracted for information about symptoms, smoking history, chronic illnesses, and
pulmonary function data. All inpatient, outpatient and pharmacy utilisation data for
each subject for 1999 were extracted from the database. Total costs for each
individual were transformed to a log scale. Potential causes of cost variability
(predictor variables) were defined and classified into sets (or domains). Multiple
linear regression models were fitted for each domain.
The study demonstrated that severity of airflow obstruction, as assessed by FEV1%
predicted, is a significant but weak predictor of future healthcare resource
utilisation—prior hospitalisation and home oxygen use, the presence of comorbid
conditions and symptoms of dyspnoea are better predictors of costs. Those
interested in the economic benefits of new COPD treatments and disease manage-
ment programs need to carefully account for these factors.
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Chronic obstructive pulmonary disease (COPD) is a
multi-component disease involving airway inflam-
mation, muco-ciliary dysfunction, airway and par-
enchymal structural changes, and expiratory
airflow obstruction.1 These components result in a
complex of symptoms and physiological changes
which affect the ability of patients to function, and
ultimately, threaten survival.
There is growing awareness of the burden of
COPD. In 2000, COPD was the fourth leading cause
of death in the USA2 and the fifth leading cause of
mortality worldwide.3 Furthermore, mortality from
COPD is projected to increase to the third leading
cause of mortality by 2020.4 Likewise, morbidity
from COPD is considerable, with the disease
predicted to be the fifth leading cause of disability
worldwide by 2020.5 The economic consequences
of COPD are considerable, due both to the high
healthcare resource utilisation required by suf-
ferers, and to indirect costs from work loss and
mortality.6–9 Exacerbations of the disease are
particularly costly and contribute to increased
disease progression, thereby increasing the like-
lihood of further exacerbations.10,11 In the USA in
1995, the hospitalisation cost of managing acute
exacerbations of chronic bronchitis was almost 40
times higher ($1592 million) than the outpatient
cost (just under $40 million).12
Fortunately, a number of new COPD treatments
have been investigated in clinical trials finding
positive results in a range of outcomes including
lung function parameters, exacerbation rates and
health status.13–15 However, healthcare payers
increasingly are charged with making their deci-
sions based on solid clinical evidence, and proving
the cost–benefit of new treatments is proble-
matic.16 Most cost analyses are based on rando-
mised clinical trial data, which invariably use highly
selective inclusion and exclusion criteria and thus
may not accurately reflect COPD patients treated in
the general population. Even the basic systems of
defining COPD severity are suspect because of their
lack of validation in prospective, cross-sectional, or
population-based studies.17 One efficient approach
to this problem is to compare the results of
randomised clinical trials to cross-sectional popula-
tion-based data. Retrospective analysis of adminis-
trative databases has proved highly useful in
obtaining information about associations between
treatments, health outcomes and healthcare re-
source utilisation in real-life populations.18–20
This study aimed to identify the factors most
predictive of future costs in COPD, and to develop a
model that best determined the causes of costvariations in this disease, based on data derived
from a large population-based cohort of patients
enrolled in a regional managed care system. A
secondary aim was to examine how well the
severity system recommended by the current GOLD
guidelines predicted future costs.1Methods
Patients
The model was based on data extracted from the
Lovelace Health Plan (LHP), a health management
organisation that serves over 200,000 members in
the New Mexico area of the USA. Study subjects
were required to have each of the following: (1) a
diagnosis of COPD, defined as having had at least
two outpatient encounters or one hospital admis-
sion coded as chronic bronchitis (491.x), emphyse-
ma (492.x), or chronic airway obstruction (496)
during calendar year 1998; 2) be age 40 or older as
of January 1, 1998; and, (3) have continuous
enrolment in the LHP during the study period
(January 1, 1998–December 31, 1999). A total of
2182 patients were identified who were classified
as having COPD and had at least some healthcare
resource utilisation during 1998. Of these, a total of
2116 patients also recorded some healthcare
resource utilisation during 1999, with three pa-
tients recording no healthcare resource utilisation
in 1999 and the remaining patients assumed to have
died or left the LHP. The medical records of these
2116 patients were abstracted for information
about symptoms, smoking history, radiographs,
and pulmonary function data. Over 95% of this
cohort had documentation of a least two clinical
factors consistent with COPD (spirometry data,
chronic respiratory symptoms or frequent bronchi-
tis episodes, radiographic changes consistent with
COPD, or cigarette smoking), so we conclude that
our case ascertainment system was reliable.
Cost and comorbidity data
Data for all inpatient and outpatient encounters
and prescription drug fulfillment for each study
subject during the study period were abstracted
from LHP administrative data. Data elements
extracted from outpatient billing records included
the date and location of service, principal and
secondary diagnoses, and total charges. For in-
patient records, we also extracted the date of
admission and discharge, length of stay, diagnosis
related group, and surgical procedures, if any.
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from the charge data. Data extracted from phar-
macy records included fulfillment date, drug,
amount, strength, average wholesale price, and
therapeutic classification. Pharmacy costs were
based on the average wholesale price of each
prescription drug fulfillment. A detailed summary
of these costs has been published elsewhere.19
The LHP administrative data was also used to
identify and classify comorbidies. We used a
modified version of the Charlson–Deyo index for
our classification scheme, requiring that a patient
have at least two outpatient codes or one inpatient
code within a category to be counted as having that
disease.21,22
Model development
The goals of the model development were to
identify the clinical factors during calendar year
1998 that were predictive of total healthcare costs
in 1999, and then to develop predictive models that
identified which of these factors had the strongestTable 1 Domains and predictive factors.
Domain Binary co
1
Demographic characteristics Age less
Male
Smoking status Former s
Current s
Prior utilisation (in 1998) Admitted
Used hom
Clinical characteristics (in 1998) Complain
Complain
Complain
Comorbidities (in 1998) Cardiova
Rheumat
Peptic ul
Psychiatr
Diabetes
Malignan
Cerebrov
Renal dis
Dementia
Hepatic d
Disease severity (FEV% predicted in 1998) 50–80%
35–50%
o35%
Includes coronary artery disease, congestive heart failure, co
yIncludes moderate to severe degenerative or osteo-arthritis, aassociation with costs and best explained the
causes of cost variability. Total costs for the sample
of 2116 individuals were transformed to a log scale
to shorten the long right tail, lessen heteroscedas-
ticity and decrease the influence of outliers,23 and
plotted to examine the distribution. Potential
causes of cost variability (predictor variables) were
defined and classified into sets (or domains), with
each predictor assigned a binary code (Table 1).
Multiple linear regression models were fitted for
each domain, using SAS software (SAS Institute,
Cary, NC, USA). Factors having a significant impact
on cost variability were defined as those with a P-
value of o0.05. The natural antilog of the
regression coefficient was used to calculate the
ratio of costs compared with the reference group.
Predictive power of fitted models
The predictive power of the proposed model was
evaluated by randomly selecting 100 individuals
from the sample of 2116 to use as a validation data
set. A regression model, using all possible subsetsde for predictive factors (abbreviation)
0
than 50 years Age 50 years or over
Female
moker Never/current smoker
moker Never/former smoker
to hospital Not admitted
e oxygen No home oxygen
ed of dyspnoea No complaint of dyspnoea
ed of wheeze No complaint of wheeze
ed of cough No complaint of cough
scular disease No such diagnosis
ic conditionsy No such diagnosis
cers, gastritis, reflux No such diagnosis
ic conditions No such diagnosis
No such diagnosis
cy No such diagnosis
ascular conditions No such diagnosis
ease No such diagnosis
No such diagnosis
isease No such diagnosis
480%
480%
480%
r pulmonale, arrhythmias, peripheral vascular disease.
uto-immune disease such as lupus, rheumatoid arthritis.
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D.W. Mapel et al.1328of predictive domains, was fitted to the remaining
patients. The fitted model was then used to
generate predicted costs for each individual in
the validation data set. Two measures of the overall
predictive power of the fitted regression model
were used: the square root of the mean squared
prediction error (RMSPE) and the mean of the
absolute prediction error (MABSPE). RMSPE gives an
estimate of the true average deviation between
predicted and observed costs for any subsequent
patients with COPD, and is calculated as
RMSPE ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃPðCobserved  CpredictedÞ2
q
nvalidation
.
The MABSPE provides a more intuitive measure of
the variability around the estimate that is less
sensitive then the RMSPE to outliers in the valida-
tion set, and calculated as
MABSPE ¼
P
ijCobserved  Cpredictedj
nvalidation
.
Each measure of prediction error was used to
select the five models that resulted in the smallest
error. This procedure was repeated ten times, using
a different set of individuals in the validation data
set. The predictors for the models for eachTable 2 Demographic and clinical characteristics.
Characteristics Males (n ¼ 1074)
Age in 1999 (years) 70.9 (range 34–98)
Former smokers (%) 61.3%
Current smokers (%) 28.4%
Mean pack years/smoker 56.8
Home oxygen (%) 32.1%
Dyspnoea (%) 60.4%
Wheeze (%) 38.6%
Cough (%) 9.5%
Mean no. comorbid conditions 2.3 (range 0–9)
Cardiovascular disease (%) 42.9%
Rheumatic conditions (%) 26.4%
Peptic ulcers, gastritis, reflux (%) 30.6%
Psychiatric conditions (%) 17.4%
Diabetes (%) 11.8%
Malignancy (%) 8.1%
Cerebrovascular conditions (%) 6.9%
Renal disease (%) 5.6%
Dementia (%) 3.9%
Hepatic disease (%) 3.7%
FEV1% predicted 60.1% (range 43–77%
Excluding COPD.validation data set were recorded, and the propor-
tion of models including these predictors assessed.Results
Patients
Demographic and clinical characteristics of the
patients used to develop the model are shown in
Table 2. Smoking status was not available for 144
men and 162 women, while spirometry results were
not available for 537 men and 533 women. Fig. 1
summarises the costs incurred in managing the
patients. A histogram of the costs incurred by each
individual in the analysis, transformed to the log
scale, is shown in Fig. 2. The marginal distribution
of log(cost) was approximately Gaussian, though
some slight degree of right skew was apparent.
Consequently, the conditional distribution of log(-
cost) was modelled assuming normal errors.
Modelling
The factors identified as having a significant impact
in multiple linear regression models when indivi-
dual domains were examined are summarised inFemales (n ¼ 1042) Total (n ¼ 2116)
71.2 (range 32–99) 71.1 (range 32–99)
50.0% 55.8%
29.4% 28.9%
46.9 52.2
31.9% 31.6%
53.7% 57.1%
37.8% 38.2%
9.8% 9.6%
2.4 (range 0–10) 2.3 (range 0–10)
35.0% 39.0%
42.2% 34.2%
29.8% 30.2%
24.5% 20.9%
13.5% 12.7%
7.6% 7.8%
4.5% 5.7%
4.3% 5.0%
4.2% 4.1%
2.8% 3.3%
) 51.2% (range 36–65%) 55.5% (range 39–71%)
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Figure 1 Healthcare costs in 1999.
Predicting the costs of COPD 1329Table 3. Patients using home oxygen or with a
hospital admission in 1998 were 79% and 64% more
costly, respectively, than those who did not require
these resources in 1998. Costs increased progres-
sively as lung function declined. Males and those
aged less than 50 years were less costly than the
comparator group by 12% and 51%, respectively.
Current smokers were associated with a significant
reduction in costs (by 40%), while former smokers
were 21% more expensive than the comparator
group.
Combining domains resulted in loss of signifi-
cance of some factors, due to multi-colinearity
(e.g. all patients using home oxygen also being
former smokers, age and dyspnoea being positively
correlated with increased disease severity) and
reduced data (e.g. loss of significance of cerebro-vascular conditions). Table 4 shows the factors that
had a significant effect on the model to account for
variability of costs, when all predictive domains
were included. In this analysis, males showed a
significant reduction in costs of 14% compared with
females, while current smokers showed a 31%
reduction in costs over the comparator group.
Costs were increased by around 40% in those using
home oxygen or having a hospital admission in the
previous year, and in those with comorbid condi-
tions.
As hospital admissions are a key cost driver, the
probability of being admitted to hospital in 1999
was also modelled. Age, gender, smoking status and
disease severity were found not to be significant
predictive factors. However, a hospital admission in
the previous year, use of home oxygen, reported
ARTICLE IN PRESS
Table 3 Predictive factors in multiple linear regression models by domains.
Domain Predictive factor Regression coefficient Ratio of costs P-value
Demographic characteristics Male 0.12329 0.88 0.0310
Age less than 50 years 0.70503 0.49 o0.0001
Smoking status Former smoker 0.19384 1.21 0.0237
Current smoker 0.51790 0.60 o0.0001
Prior utilisation Admission 0.49733 1.64 o0.001
Home oxygen 0.58119 1.79 o0.001
Clinical characteristics Dyspnoea 0.43242 1.54 o0.001
Comorbidities Cardiovascular disease 0.49744 1.64 o0.001
Rheumatic conditions 0.24188 1.27 o0.001
Peptic ulcers, gastritis, reflux 0.24274 1.27 o0.001
Psychiatric conditions 0.29775 1.35 o0.001
Diabetes 0.24790 1.28 0.0031
Malignancy 0.48889 1.63 o0.001
Cerebrovascular conditions 0.26867 1.31 0.0259
Renal disease 0.26834 1.31 0.0390
FEV1% predicted 50–80% 0.22097 1.25 0.0473
35–50% 0.39201 1.48 0.0014
o35% 0.53718 1.71 o0.001
Table 4 Predictive factors in multiple linear regression models, combining all domains.
Domain Predictive factor Regression coefficient Ratio of costs P-value
Demographic characteristics Male 0.14918 0.86 0.0338
Smoking status Current smoker 0.37082 0.69 0.0020
Prior utilisation Admission 0.37429 1.45 o0.0001
Home oxygen 0.30035 1.35 o0.0001
Comorbidities Cardiovascular disease 0.33038 1.39 o0.0001
Rheumatic conditions 0.20805 1.23 0.0039
Peptic ulcers, gastritis, reflux 0.18884 1.21 0.0090
Psychiatric conditions 0.32713 1.39 0.0001
Diabetes 0.36711 1.44 0.0005
Malignancy 0.59836 1.82 o0.0001
Renal disease 0.36177 1.44 0.0287
FEV1% predicted 35–50% 0.22952 1.26 0.0496
D.W. Mapel et al.1330dyspnoea and some comorbid conditions were all
significant factors predictive of hospital admission
(Fig. 3).Predictive power of fitted models
While dyspnoea and demographic characteristics
were included in under half of the best predictive
models (44% and 46%, respectively), prior health-
care resource utilisation (hospital admissions andhome oxygen use) was included in 62% and
comorbid conditions included in 68% of the best
predictive models, indicating that these latter
factors are most strongly predictive of future costs.
However, the average prediction error was very
high. Using RMSPE, the average deviation between
the predicted and expected costs over the valida-
tion data set ranged from $11,253 to $61,655, with
marked variation between validation sets used.
Likewise, there was considerable variation in
prediction error calculated using MABSPE.
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The study demonstrated that the currently recom-
mended system for staging airflow obstruction1 is a
valid but weak predictor of future healthcare
resource utilisation—prior hospitalisation and
home oxygen use, the presence of comorbid
conditions and symptoms of dyspnoea are better
predictors of costs.
The patients enrolled in the LHP used as the basis
for the model present a typical population of
patients with COPD. In this study, 58% of patients
had FEV1 of 50% predicted or more, with 24% having
lung function of 35–49% predicted and 18% with
FEV1 less than 35% predicted, comparable to
populations of patients with COPD derived from
the Health Survey for England24 and from the Third
National Health and Nutrition examination Survey
(NHANES III) in the USA.25 Furthermore, use of
home oxygen (a factor with a significant impact on
costs) was comparable in the present study and in
that reported by US patients in the confronting
COPD study.26 Consequently, the findings of the
present study are likely to be applicable to other
populations.
The present study used information derived from
a large database covering a population of some
200,000 people. Thus, the study population reflects
real world data, encompassing patients suffering
from multiple comorbid conditions—such patients
may be excluded from randomised controlled
clinical trials. The use of an administrative data-
base also allows investigation of outcomes of
interest to healthcare decision-makers, namely
inpatient, outpatient and pharmacy costs. Such
database studies are proving of great value in thestudy of COPD, as they allow the capture of
information about intermittent severe events, such
as exacerbations, which may be difficult to study in
short-term studies that exclude many patients at
greatest risk of experiencing these adverse
events.27 Exacerbations of COPD have been shown
to have a major impact on patient quality of life, as
well as on disease progression, mortality and
costs.10,28–30
A standard methodology for the handling of data
with skewed distribution was used in this study.23
Cost data was transformed logarithmically, with
exclusion of data from the three patients who did
not have healthcare resource utilisation during
1999 (i.e. zero cost). Analysis of utilisation data
on a log scale also facilitates the use of a multi-
plicative model for interaction between potential
predictive factors because the exponential of the
regression coefficients provides estimated ratios of
costs. Other methods of analysing skewed data,
such as Cox regression, result in regression coeffi-
cients that are more difficult to interpret in the
context of medical costs, as they pertain to hazard
ratios.23
One limitation of this analysis is that we required
all patients to be continuously enrolled throughout
the study period, thus excluding persons who died.
We did this because of the profound increase in
costs that occur at the end of life, which cause
these patients to be statistical outliers with
disproportionate effects on the overall results if
included in the analysis. Therefore, our analysis
assumes that all patients will survive the following
year, and that is an important consideration
when comparing our results to other populations.
We have conducted a separate analysis of the
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D.W. Mapel et al.1332healthcare costs incurred in the last 12 months of
life among persons treated by the LHP, and found
that COPD patients had an average total cost of
$48,384, which was approximately four times
greater than that of the survivors. However, it is
likely that the main findings of this study still apply
to COPD patients who die. In studies of COPD
survival, some of the main predictors of death have
included most of the same factors that we found to
be predictive of increased costs, such as advanced
age, hospitalisations, and the presence of comor-
bidities.31–33
Regression analysis, although unsatisfactory for
predicting healthcare utilisation of an individual,
can be used to give meaningful predictions for a
population. Such models are useful for healthcare
planners and decision-makers. By identifying the
factors that have the largest influence on future
costs, they can direct decision-makers to the most
appropriate outcomes for evaluation of potential
treatments. This study showed that previous
healthcare resource utilisation (prior hospitalisa-
tion or home oxygen use) was the most important
determinant of future cost. Prior hospitalisations
are usually the result of an exacerbation,34 while
failure of therapy to prevent exacerbations pro-
gressing to hospitalisation has been demonstrated
to result in costs of $100/exacerbation.30 Our study
suggests that management strategies for COPD
should put greater emphasis on reducing exacerba-
tions and hospitalisations and on controlling chronic
symptoms, as opposed to simply focusing on how
treatments effect the FEV1.
The severity of airflow limitation, as measured by
% predicted FEV1 and used in classifications of
disease stages, was shown in this study to be a valid
but weak predictor of healthcare utilisation. How-
ever, it should be noted that only the patients who
survived the full period of 1998 and 1999 were
included in the analysis, excluding those who died
during the study period. Several studies have
highlighted the link between disease stage and
mortality risk, with lung function both an indepen-
dent predictor of mortality and a marker for other
changes.35,36 Those who died during the period
were likely to be those with most severely impaired
lung function. As many costs are incurred in the
period shortly before death, this would have the
effect of blunting the predictive effect of lung
function on healthcare resource utilisation.
Interestingly, this study found that current
smokers were associated with lower costs, and
former smokers with higher costs, than the com-
parator groups. A similar finding has also been
reported in studies of completely different design,
such as the large scale international patient survey,Confronting COPD.37 This finding is likely to be due
to the impact of the ‘quitting ill’ effect, in which
smokers quit only after the onset of severe
symptoms.26
Although the present study clearly identified the
factors that are predictive of future costs, the
magnitude of the prediction error was consider-
able. This means that the impact of these factors
cannot be readily assigned a monetary value. The
degree of error was largely determined by the
composition of patients within the validation data
set. When the validation set included some patients
who incurred high costs, then the prediction error
was correspondingly large. When such patients
were not included in the validation data set, then
the prediction error was relatively small. The
predictive model does not account for factors that
could influence whether an individual is in a high
cost group or not. In the future, this may be
addressed by refining the model to incorporate two
stages: firstly, predicting whether or not hospitali-
sation would occur, then secondly, assessing the
subsequent costs.
In conclusion, the study showed that the key
predictors of future healthcare costs for a popula-
tion of patients with COPD are prior hospitalisation
and use of home oxygen. With the increasing
prevalence and high cost of managing COPD, the
study underlines the need for management strate-
gies that reduce the frequency and severity of
exacerbations, thereby reducing the need for
hospitalisation and delaying disease progression.References
1. Global Initiative for Chronic Obstructive Lung Disease
(GOLD). GOLD Workshop Report (Updated 2003). Accessed
at www.goldcopd.com, March 25th, 2004
2. Minino AM, Smith BL. Preliminary data for 2000. National
Center for Health Statistics. National Vital Statistics
Reports, No. 49(12). Hyattsville, MD, 2001.
3. Murray CJ, Lopez AD, Mathers CD, Stein C. The global burden
of disease 2000 project: aims, methods and data sources.
Global Programme on Evidence for Health Policy Discussion
Paper No. 36. World Health Organisation, November 2001
(revised).
4. Murray CJ, Lopez AD. The Global Burden of Disease: a
comprehensive assessment of mortality and disability from
disease, injuries and risk factors in 1990 and projected to
2020. Cambridge: Harvard University Press; 1996.
5. Murray CJ, Lopez AD. Alternative projections of mortality
and disability by cause 1990–2020: Global Burden of Disease
Study. Lancet 1997;249:1498–504.
6. Sullivan SD, Ramsey SD, Lee TA. The economic burden of
COPD. Chest 2000;117(Suppl. 2):5S–9S.
7. Friedman M, Hilleman DE. Economic burden of chronic
obstructive pulmonary disease. Impact of new treatment
options. Pharmacoeconomics 2001;19:245–54.
ARTICLE IN PRESS
Predicting the costs of COPD 13338. Faulkner MA, Hilleman DE. The economic impact of chronic
obstructive pulmonary disease. Expert Opin Pharmacother
2002;3:219–28.
9. Jacobson L, Hertzman P, Lofdahl CG, Skoogh BE, Lindgren B.
The economic impact of asthma and chronic obstructive
pulmonary disease (COPD) in Sweden in 1980 and 1991.
Respir Med 2000;94:247–55.
10. Andersson F, Borg S, Jannson SA, et al. The costs of
exacerbations in chronic obstructive pulmonary disease
(COPD). Respir Med 2002;96:700–8.
11. Hilleman DE, Dewan N, Malesker M, Friedman M. Pharma-
coeconomic evaluation of COPD. Chest 2000;118:1278–85.
12. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian
R. Treatment cost of acute exacerbations of chronic
bronchitits. Clin Ther 1999;21:576–91.
13. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol
and fluticasone in the treatment of chronic obstructive
pulmonary disease: a randomised controlled trial. Lancet
2003;361:449–56.
14. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA,
Maslen TK. Randomised, double blind, placebo-controlled
study of fluticasone propionate in patients with moderate to
severe chronic obstructive pulmonary disease: the ISOLDE
trial. BMJ 2000;320:1297–303.
15. Vincken W, van Noord JA, Greefhorst AP, et al. Improved
health outcomes in patients with COPD during 1 year’s
treatment with tiotropium. Eur Respir J 2002;19:209–16.
16. Levine M, Taylor R, Ryan M, Sculpher M. Decision-making by
healthcare payers. Respir Med 2002;96(Suppl. C):S31–8.
17. Huib AMK. The GOLD classification has not advanced under-
standing of COPD. Am Rev Respir Crit Care Med 2004;170:
212–3.
18. Sin DD, Tu JV. Inhaled corticosteroids and the risk of
mortality and readmission in elderly patients with chronic
obstructive pulmonary disease. Am J Respir Crit Care Med
2001;164:580–4.
19. Mapel DW, Hurley JS, Frost FJ, Peterson HV, Picchi MA,
Coultas DB. Health care utilization in chronic obstructive
pulmonary disease: a case-control study in a health main-
tenance organization. Arch Intern Med 2000;160:2653–8.
20. Mapel DW, Pearson M. Obtaining evidence for use by
healthcare payers on the success of chronic obstructive
pulmonary disease management. Respir Med 2002;96(Suppl.
C):S23–30.
21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new
method of classifying prognostic comorbidity in longitudinal
studies: development and validation. J Chron Dis 1987;40:
373–83.
22. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comor-
bidity index for use with ICD-9-CM administrative databases.
J Clin Epidemiol 1992;45:613–9.23. Diehr P, Yanez D, Ash A, Hornbrook M, Lin DY. Methods for
analyzing health care utilization and costs. Ann Rev Public
Health 1999;20:125–44.
24. Macran S, Kind P, Spencer M. Predicting quality of life in
chronic obstructive pulmonary disease. Eur Respir J 2002;
20(Suppl. 38):156s.
25. Coultas DB, Mapel D, Gagnon R, Lydick E. The health impact
of undiagnosed airflow obstruction in a national sample of
United States adults. Am J Respir Crit Care Med 2001;
164:372–7.
26. Halpern MT, Stanford RH, Borker R. The burden of COPD in
the USA: results from the confronting COPD survey. Respir J
2002;97(Suppl. C):S81–9.
27. Spencer MD. Economic implications of reductions in COPD
re-hospitalisation due to treatment with inhaled corticos-
teroids. Thorax 2002;579(Suppl. 3 iii 59):P41.
28. Connors AF, Dawson NV, Thomas C, et al. Outcomes following
acute exacerbations of severe chronic obstructive lung
disease. Am J Respir Crit Care Med 1996;154:959–67.
29. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ,
Wedzicha JA. Time course and recovery of exacerbations in
patients with chronic obstructive pulmonary disease. Am J
Respir Crit Care Med 2000;161:1608–13.
30. Miravitlles M, Murio C, Guerrero T, Gisbert R. Pharmacoe-
conomic evaluation of acute exacerbations of chronic
bronchitis and COPD. Chest 2002;121:1449–55.
31. Sin DD, Tu JV. Inhaled corticosteroids and the risk of
mortality and readmission in elderly patients with chronic
obstructive pulmonary disease. Am J Respir Crit Care Med
2001;164:580–4.
32. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC.
Survival in COPD patients after regular use of salmeterol
and/or fluticasone propionate in general practice. Eur Resp
J 2002;20:1–7.
33. Soriano JB, Kiri VA, Pride NB, Vestbo J. Inhaled corticoster-
oids with/without long-acting b-agonists reduce the risk of
rehospitalization and death in COPD patients. Am J Respir
Med 2003;2:67–74.
34. Price MJ, Hurrell C, Efthimiou J, Medley HV. Health care
costs of treating exacerbations of chronic obstructive
pulmonary disease. Eur Respir J 1999;14:30s.
35. Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung
function and mortality in the United States: data from the
first National Health and Nutrition Examination Survey
follow up study. Thorax 2003;58:388–93.
36. Anthonisen NR, Connett JE, Enright PL, Manfreda J.
Hospitalizations and mortality in the lung health study. Am
J Respir Crit Care Med 2002;166:333–9.
37. Wouters EFM. Economic analysis of the Confronting COPD
survey: overview of results. Respir J 2002;97(Suppl.
C):S3–S14.
